CD40 Ligand antibody (AA 47-258) (FITC)

Catalog No. ABIN7147158

The Rabbit Polyclonal anti-CD40 Ligand antibody has been validated for . It is suitable to detect CD40 Ligand in samples from Human.

Quick Overview for CD40 Ligand antibody (AA 47-258) (FITC) (ABIN7147158)

Target: CD40 Ligand (CD40LG)

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CD40 Ligand antibody is conjugated to FITC

Application: Please inquire

Product Details anti-CD40 Ligand Antibody (FITC)

Binding Specificity: AA 47-258

Purpose: CD40LG Antibody, FITC conjugated

Purification: Protein G purified

Purity: >95 %

Immunogen: Recombinant Human CD40 ligand protein (47-258AA)

Isotype: IgG

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for CD40 Ligand

Target: CD40 Ligand (CD40LG)

Alternative Name: CD40LG

Background:

Background: Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL-4. Involved in immunoglobulin class switching.

Aliases: CD 40L antibody, CD154 antibody, CD40 antigen ligand antibody, CD40 ligand antibody, CD40 ligand, soluble form antibody, CD40-L antibody, CD40L antibody, CD40L_HUMAN antibody, CD40LG antibody, gp39 antibody, hCD40L antibody, HIGM1 antibody, IGM antibody, IMD3 antibody, T B cell activating molecule antibody, T BAM antibody, T-cell antigen Gp39 antibody, TNF-related activation protein antibody, TNFSF5 antibody, TrAP antibody, Tumor necrosis factor (ligand) superfamily member 5 antibody, Tumor necrosis factor ligand superfamily member 5 antibody

UniProt: P29965

Pathways: NF-kappaB Signaling, Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints